Cordis Acquires MedAlliance

October 17, 2022

Cordis, the interventional cardiovascular device company, announced the acquisition of Switzerland-based MedAlliance, developer of the SELUTION SLR sirolimus drug‑eluting balloon. The deal includes an initial $35M investment, $200M payable at closing (expected 2023), plus up to $125M in regulatory milestones and up to $775M in commercial milestones through 2029; Cordis will begin co-promotion of SELUTION SLR in markets where it is available.

Buyers
Cordis
Targets
MedAlliance
Industry
Medical Devices
Location
Vaud, Switzerland
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.